Clarivate

Overview

Clarivate (NYSE: CLVT) is a global information services company carved out of Thomson Reuters in 2016, providing transformative intelligence through enriched data, predictive analytics, workflow solutions, and expert services. The company’s Life Sciences & Healthcare (LS&H) division — generating $389.8M in annual revenue (declining 6.9% year-over-year) — serves pharmaceutical companies with tools for competitive intelligence, regulatory tracking, pipeline analysis, real-world data analytics, and market access consulting.

Total company revenue stands at $2.46B (declining from a $2.66B peak), with a market capitalization of approximately $1.47B. The company carries $4.47B in debt against that revenue base, resulting in a severe net leverage ratio of 7.7x and annual interest payments of approximately $220-250M. This financial overhang is the dominant factor shaping Clarivate’s strategic options, culminating in a February 2026 announcement that the company is pursuing a sale of the entire LS&H division, which sent the stock surging 30-40%.

Despite the financial challenges, Clarivate’s core Cortellis platform remains genuinely best-in-class for regulatory and CMC intelligence, used by 100% of the top 20 pharma companies.

Services & Capabilities

Competitive & Regulatory Intelligence

• Cortellis suite: Flagship platform covering 800K+ drugs, 700K+ clinical trials, and 300K+ regulatory documents
  • Cortellis Competitive Intelligence & Analytics
  • Cortellis Regulatory Intelligence
  • Cortellis Drug Discovery Intelligence
  • Cortellis Deals Intelligence
  • Cortellis Generics Intelligence
• BioWorld: News and analysis service for biotech and pharma deal intelligence

Real-World Data & Analytics

• DRG Fusion (launched January 2025): Modular, next-generation RWD analytics platform
• US specialty pharmacy claims data (500+ drugs)
• RWD consulting team of 300+ professionals
• Disease landscape and treatment pathway analytics
• Patient journey analytics

Consulting & Advisory

• R&D strategy and portfolio optimization
• HEOR (Health Economics & Outcomes Research)
• Market access strategy and payer intelligence
• Fingertip Formulary Suite (formulary coverage tracking)
• Commercial strategy consulting
• PhD-level expert consulting team

Additional Platforms

• Web of Science (academic/scientific citation index)
• OFF-X Translational Safety
• Drug Safety Triager
• Healthbase
• Global QMS (regulatory compliance SaaS, acquired April 2024)

Competitive Position

Clarivate’s competitive position is bifurcated: dominant in regulatory/CMC intelligence (Cortellis), but increasingly challenged in commercial analytics and RWD.

Where Clarivate leads:

• Cortellis is the gold standard for regulatory intelligence, pipeline tracking, and competitive analysis. 100% of top 20 pharma are customers. No competitor matches its depth in regulatory/CMC data.
• Decades of curated datasets from legacy Thomson Reuters sources provide historical depth no one can replicate.

Where Clarivate is losing ground:

• Commercial analytics and RWD: IQVIA dominates with claims data scale; Komodo Health and Definitive Healthcare are gaining with modern platforms
• AI/ML capabilities lag behind newer entrants
• DRG Fusion (Jan 2025) is the response but is still early in market adoption

Key competitors:

• Pipeline/CI: IQVIA (Evaluate), Evaluate (now part of Norstella), Citeline
• RWD: IQVIA, Komodo Health, Inovalon, Definitive Healthcare
• Market access: MMIT (Norstella), Fingertip Formulary (own product)
• Regulatory: Veeva Vault RIM, MasterControl

Recent Developments

• February 2026: Announced strategic review and pursuit of sale of entire LS&H division. Stock surged 30-40% on the news. Active discussions with potential buyers reportedly underway.
• January 2025: Launched DRG Fusion, a modular next-generation life sciences analytics platform powered by real-world data.
• Q4 2025: First GAAP-profitable quarter since 2019, signaling some operational improvement despite revenue decline.
• Late 2024: Approximately 200 position eliminations as part of cost restructuring.
• December 2024: Authorized $500M share repurchase program.
• April 2024: Acquired Global QMS for regulatory compliance SaaS capabilities.
• March 2024: Acquired MotionHall AI assets for life sciences intelligence.

Client & Partner Ecosystem

• Penetration: All top 30 pharma and top 10 biotech companies use Clarivate products
• Named clients: Menarini (patient centricity strategy), Gedeon Richter (regulatory workflow), Asahi Kasei, Cleo Diagnostics
• Coverage: Top 20 medtech companies
• Consulting clients: R&D, commercial, and strategy teams across pharma/biotech/medtech

Technology Platform

Platform	Function	Status
Cortellis	Pipeline CI, regulatory intelligence, drug discovery, deals, generics	Best-in-class; 800K+ drugs, 700K+ trials, 300K+ regulatory docs
DRG Fusion	Modular RWD analytics platform	Launched Jan 2025; early adoption phase
BioWorld	Biotech/pharma news and deal intelligence	Established
Fingertip Formulary	Formulary coverage tracking	Niche but valued
Web of Science	Academic citation and research index	Non-LS&H but significant brand asset
OFF-X / Drug Safety Triager	Translational safety and drug safety analytics	Specialized tools

Therapeutic Focus

Broad coverage across all therapeutic areas. Cortellis data spans the full drug development landscape with no specific therapeutic specialization.

Sources

• Clarivate Homepage
• About Us
• Life Sciences & Healthcare
• Cortellis Competitive Intelligence
• Consulting Services
• RWD News
• PR Newswire DRG Fusion
• StockAnalysis
• raw/research/clarivate.pplx.md